ResMed edges higher after mixed analyst signals, shares trade near recent targets
22.06.2026 - 21:48:54 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 21:44.
ResMed Inc. (US7611521078) starts the new week with its NYSE-listed shares trading around 189 US dollars and a market value near 27.5 billion dollars. The sleep-apnea specialist sits in the S&P 500 healthcare cohort, with several Wall Street houses updating their views this month according to recent US market reports.
What analysts are signaling now
KeyBanc Capital Markets recently trimmed its 12-month price target for ResMed to 266 US dollars from 290 dollars while reiterating an Overweight rating, pointing to a still constructive stance on the shares despite valuation adjustments as a Marketscreener summary of the KeyBanc note shows. Morgan Stanley, by contrast, moved to a more cautious view, downgrading ResMed from Overweight to Equal Weight and lowering its target from 286 to 230 dollars, citing a more balanced risk-reward profile after the recent recovery in the shares as reflected in a Morgan Stanley update excerpted on Robinhood.
Across Wall Street, data compiled by MarketBeat indicate an average analyst price target around 188.8 US dollars for ResMed, broadly in line with where the stock most recently closed on the NYSE, implying limited immediate upside at current levels based on the latest MarketBeat consensus overview. A separate snapshot from Public.com counts 10 analysts on the name with an overall Buy consensus rating and an average target near 277.8 dollars, illustrating how different data sets can diverge depending on methodology and update timing according to a current Public.com analyst survey.
How the shares trade in New York and Sydney
On the NYSE, ResMed shares recently changed hands around 189.47 US dollars, with intraday trading on 2026-06-22 spanning a range from 187.25 to 190.73 dollars, placing the price roughly 1.2 percent above the day’s low and 0.7 percent below the high according to Robinhood’s live quote data for ticker RMD. That level leaves the stock trading close to some consensus targets while still below the more optimistic objectives from houses such as KeyBanc.
In parallel, the Australian listing on the ASX under ticker RMD most recently closed at 26.95 Australian dollars, up about 1.01 percent on the day and roughly 2.8 percent higher than a week earlier, but still around 40 percent below its 12?month high of 45.14 dollars as price data from Intelligent Investor for ASX:RMD indicate. The dual listing gives investors in both the US and Australia access to the same underlying business, with currency movements adding an extra layer of consideration for cross-market comparisons.
All news and analysis on the ResMed shares
Further updates on analyst views, quarterly figures and price developments for ResMed can be found in the dedicated topic area on ad-hoc-news.de and via the company’s Investor Relations site.
The products behind the ticker RMD
ResMed generates its revenue primarily from respiratory-care devices, with a focus on obstructive sleep apnea and chronic obstructive pulmonary disease. A representative product is the AirSense 11 continuous positive airway pressure device, which delivers pressurized air through a mask to help patients maintain open airways during sleep and connects to cloud-based software for remote monitoring.
Where the stock trades today
The ResMed shares (US7611521078) last traded on the NYSE at 189.47 US dollars on 2026-06-22, 15:59 Eastern time.
Key data on the ResMed shares
- Company: ResMed Inc.
- ISIN: US7611521078
- WKN: 895026
- Ticker: RMD
- Trading venue: NYSE
- Price (as of 2026-06-22, 15:59): 189.47 USD
- Market cap: 27.48 billion USD (as of 2026-06-22)
- Sector / industry: Health Care Equipment & Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any financial instrument, or a solicitation of any transaction. Historical data and analyst estimates are subject to change, and investors should conduct their own research or consult a qualified financial advisor before making investment decisions.
